News Story: Full Text
Sponsored By
NovoCure Trial
Please Click On The Above Banner For More Details
Braintumor Website


Comparison of survival of patients in the phase I study of motexafin gadolinium (MGd) with radiation therapy (RT) for glioblastoma multiforme (GBM), with a matched cohort of patients from the RTOG RPA glioma database


Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)



Website: http://www.asco.org/ac/1,1003,_12-002489-00_18-002003-00_19-00102399-00_29-00A,00.asp?cat=CNS+Tumors&parent=Central+Nervous+System+Tumors&returnpid=2325&SubCat_ID=4

Posted on: 06/14/2003

39th ASCO Annual Meeting • Chicago, IL • May 31-June 3, 2003 (Abstract No. 425)

Comparison of survival of patients in the phase I study of motexafin gadolinium (MGd) with radiation therapy (RT) for glioblastoma multiforme (GBM), with a matched cohort of patients from the RTOG RPA glioma database

J. M. Ford, W. Seiferheld, M. Mehta, S. Phan, W. Curran

UCLA, Los Angeles, CA; Radiation Therapy Oncology Group, Philadelphia, PA; University of Wisconsin, Madison, WI; Pharmacyclics Inc., Sunnyvale, CA; Thomas Jefferson University, Philadelphia, PA

Aim: To compare the survival of patients with GBM treated in the phase I study of motexafin gadolinium in combination with radiation, with a matched cohort of patients from the RTOG Recursive Partitioning Analysis (RPA) glioma database.

Methods: Data were available for 33 cases treated on the phase I trial. These were matched with 33 cases from the RTOG database according to the following prognostic factors: Karnofsky Performance Status, extent of surgery, histology, and age (within 5 years). Kaplan-Meier survival curves were generated. A matched pair Cox analysis of overall survival was done and the generalized Wilcoxon (Peto-Prentice) test was used for a nonparametric comparison.

Results: Kaplan-Meier estimate of median survival time for the RTOG cases was 12.0 months compared to 17.6 months for the cases treated with motexafin gadolinium. The Cox analysis of overall survival yielded a hazard ratio of 2.0 in favor of the motexafin gadolinium treated cases (p=0.07). The generalized Wilcoxon test also resulted in a one-sided p-value of 0.07.

Discussion: Studies of chemotherapy for GBM suggest at best a median survival benefit in the range of 3 months, yet chemotherapy is routinely given to many patients; therefore, a survival benefit of 5.6 months is of interest. The numbers of patients are small, but they were well matched for the major prognostic factors.

Conclusion: The results of this well matched case control comparison showed a potential survival benefit of 5 to 6 months from the use of motexafin gadolinium in combination with standard radiation therapy for Glioblastoma Multiforme.

This result should be further investigated with either a larger phase II trial or a randomized trial in a multi-center setting.

© Copyright 2003 American Society of Clinical Oncology All rights reserved worldwide

Source: http://www.asco.org/ac/1,1003,_12-002489-00_18-002003-00_19-00102399-00_29-00A,00.asp?cat=CNS+Tumors&parent= Central+Nervous+System+Tumors&returnpid=2325&SubCat_ID=4



Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740